Quantifying evidence for phenotypic specificity (PP4) for syndromic phenotypes: Large-scale integration of rare germline FH variants from diagnostic laboratory testing for HLRCC (Hereditary Leiomyomatosis and Renal Cell Cancer) and renal cancer

dc.contributor.authorAllen, Sophie
dc.contributor.authorRowlands, Charlie F.
dc.contributor.authorButler, Samantha
dc.contributor.authorDurkie, Miranda
dc.contributor.authorHorton, Carrie
dc.contributor.authorPesaran, Tina
dc.contributor.authorRichardson, Marcy
dc.contributor.authorRobinson, Rachel
dc.contributor.authorGarrett, Alice
dc.contributor.authorBurghel, George J.
dc.contributor.authorCallaway, Alison
dc.contributor.authorField, Joanne
dc.contributor.authorFrugtniet, Bethan
dc.contributor.authorPalmer-Smith, Sheila
dc.contributor.authorGrant, Jonathan
dc.contributor.authorPagan, Judith
dc.contributor.authorMcDevitt, Trudi
dc.contributor.authorSnape, Katie
dc.contributor.authorAndreaou, Avgi
dc.contributor.authorMaher, Eamonn R.
dc.contributor.authorHanson, Helen
dc.contributor.authorMcVeigh, Terri
dc.contributor.authorTurnbull, Clare
dc.contributor.authorCanVIG-UK
dc.contributor.authorLobo, Daniel
dc.contributor.authoret al.
dc.date.accessioned2026-02-03T18:14:43Z
dc.date.issued2025-03-19
dc.descriptionAuthors: CanVIG-UK Consortium, C. Turnbull1,49, A. Garrett1,47, L. Loong1, S. Choi1, B. Torr1, S. Allen1, M. Durkie2, A. Callaway3, J. Drummond4, G.J. Burghel5, R. Robinson6, I.R. Berry65, A.J. Wallace5, D.M. Eccles7, 8, M. Tischkowitz13, S. Ellard9, H. Hanson1,16, E. Baple10,11, D.G. Evans5,30, E. Woodward5,30, F. Lalloo5,30, S. Samant33, A. Lucassen57,14,15, A. Znaczko44, A. Shaw23, A. Ansari34, A. Kumar21, A. Donaldson53, A. Murray19, A. Ross18, A. Taylor-Beadling22, A. Taylor18, A. Innes25, A. Brady29, A. Kulkarni23, A.C. Hogg5, A. Ramsay Bowden18, A. Hadonou47, B. Coad16, B. McIldowie19, B. Speight18, B. DeSouza47, B. Mullaney3, C. McKenna62, C. Brewer44, C. Olimpio18, C. Clabby40, C. Crosby47, C. Jenkins42, C. Armstrong33, C. Bowles9, C. Brooks22, C. Byrne62, C. Maurer4, D. Baralle57, D. Chubb1, D. Stobo34, D. Moore35, D.O'Sullivan33, D. Donnelly62, D. Randhawa24, D. Halliday41 , E. Atkinson50, E. Rauter24, E. Johnston38, E. Maher8, E. Sofianopoulou17, E. Petrides23, F. McRonald43, F. Pelz51, I. Frayling19, G. Corbett62, G. Rea62, H. Clouston5, H. Powell31, H. Williamson52, H. Carley47, H.J.W. Thomas26, I. Tomlinson63, J. Cook46, J. Tellez32, J. Whitworth18, J. Williams49, J. Murray35, J. Campbell27, J. Tolmie33, J. Field38, J. Mason64, J. Burn31, J. Bruty18, J. Callaway8, J. Grant34, J. Del Rey Jimenez47, J. Pagan35, J. VanCampen24, J. Barwell53, K. Monahan29, K. Tatton-Brown16, K.R. Ong63, K. Murphy33, K. Andrews18, K. Mokretar23, K. Cadoo48, K. Smith52, K. Baker8, K. Brown24, K. Reay64, K. McKay Bounford34, K. Bradshaw38, K. Russell65, K. Stone23, K. Snape16, L. Crookes5, L. Reed21, L. Yarram65, L. Cobbold47, L. Walker39, L. Walker41, L. Hawkes16, L. Busby22, L. Izatt23, L. Kiely22, L. Hughes64, L. Side56, L. Sarkies18, K.-L. Greenhalgh28, M. Shanmugasundaram63, M. Duff40, M. Bartlett29, M. Watson3, M. Owens9, M. Bradford54, M. Huxley64, M. Slean33, M. Ryten23, M. Smith55, M. Ahmed21, N. Roberts2, O. Middleton33, P. Tarpey4, P. Logan62, P. Dean3, P. May24, P. Brace21, R. Tredwell38, R. Harrison37, R. Hart63, R. Kirk5, R. Martin31, R. Nyanhete3, R. Wright2, R. Martin62, R. Davidson34, R. Cleaver45, S. Talukdar16, S. Butler64, J. Sampson19, S. Ribeiro49, S. Dell46, S. Mackenzie32, S. Hegarty62, S. Albaba5, S. McKee36, S. Palmer-Smith19, S. Heggarty62, S. MacParland62, S. Greville-Heygate49, S. Daniels4,S. Prapa18,S. Abbs4, S. Tennant33, S. Hardy43, S. MacMahon49, T. McVeigh49, T. Foo49, T. Bedenham42, T. Cranston42, T. McDevitt40, V. Clowes29, V. Tripathi23, V. McConnell62, N. Woodwaer45, Y. Wallis64, Z. Kemp49, G. Mullan62, L. Pierson62, L. Rainey62, C. Joyce59, A. Timbs41, A-M. Reuther3, B. Frugtniet47, B. DeSouza25, C. Husher3, C. Lawn22, C. Corbett63, D. Nocera-Jijon16, D. Reay31, E. Cross3, F. Ryan3, H. Lindsay6, J. Oliver6, J. Dring63, J. Spiers65, J. Harper23, K. Ciucias34, L. Connolly60, M. Tsang62, R. Brown6, S. Shepherd32, S. Begum16, S. Daniels3, T. Tadiso16, T. Linton-Willoughby4, H. Heppell35, K. Sahan61, L. Worrillow6, Z. Allen22, C. Watt34,M. Hegarty62, R. Mitchell6, R. Coles66, G. Nickless23, E. Cojocaru49, I. Doal64, F. Sava64, C. McCarthy62, R. Jeeneea63, D. Goudie20, M. McConachie20, S. Botosneanu5, G. Kavanaugh1, K. Russell10, C. Sherlaw63, O. Tsoulaki46, C. Forde5, E. Petley63, A-B. Jones1, K. Oprych16, S. Pryde67, Z. Hyder5, N. Elkhateeb18, R. Braham21, L. Hanington41, C. Huntley1, R. Irving51, A. Sadan23, M. Ramos22, C. Elliot35, D. Wren22, D.Lobo35, J. McLean68, D. May18, L. Kearney48, T. Campbell38, K. Asakura68, L. Alwadi19, R. O’Shea48, J. Gabriel42, L. Chiecchio3, P. Bowman44, L.A. Sutton48, C. Walsh23, V. Cloke69, D. Ucanok37, J. Davies65, B. Pleasance65, E. Maguire6, A. Whaite70, S. Best71, S. Westbury72, A. Logan62, D. Navarajasegaran71, A. Bench35, P. Wightman34, A. Cartwright2, E. Higgs41, J.Bott42, H. Whitehouse5, J. Stevens58, D. Martin37, J. Dunlop68, S. Thomas73, C. Sau68, S. Farndon74, N. Coleman48, P. Angelini49, M. Duff59, H. Massey35, C. Rowlands1, C. Garcia-Petit68, K. Gillespie68, A. Alder68, E. Middleton68, C. Cassidy75, N. Orfali48, A. Webb3, A. Luharia64, N. Walker33, J. Charlton71, A. Andreou47, J. Peddie68, M. Khan23, L. Wilkinson31, H. Bezuidenhout47, M. Edis18, A. Callard29, P. Ostrowski76, P. Moverley51, K. Bean73, A. Dunne48, A. Moleirinho23, S. Waller5, K. Cox47, L. Greensmith28, A. Brittle5, N. Gossan5, L. Freestone4, C. Shak77, T. Langford75, Y. Clinch21, H. Livesey51, S. Borland46, A. Joshi47, K. Wall77, A. Whitworth46, A.Wilsdon37, K. Edgerley72, S. Pugh5, N. Chrysochoidi3, S. Mutch38, C. McMullan5, Y. Johnston78, M. Muraru77, A. May77, R. Begum77, C. Smith44, R. Patel47, I. Bhatnagar79, A. Taylor62, D. Brown69, J. Willan46, S. Taylor48, K. Jones21, K. Cox21, C. Ramsden75, O. Taiwo49, J. Jaudzemaite47, R. Sharmin47, L. Young34, C.O’Dubhshlaine35, L. McSorley80, S. Lillis23, P. Alexopoulos23, E. Mortensson65, L. Kingham4, R. Moore18, M. Kosicka-Slawinska81, S. Aslam65, R. Wells82, A. Carter82, H. Warren6, E. Rolf49, H. Reed75, L. Pearce83, D. Lock6, F. Ali66, A. Kolozi84, N. White48, D. Wood34, C. Hayden25, W. Cheah58, J. Sims6, R. Heron46, J. Sibbring4, L. Elmhirst35, L. Mavrogiannis6, K. Oakhill4, L. Wang28, A. Singh47, K. Doal21, L. Kettle63, R. Salmon63, G. Thodi48, C. O’Brien48, C. Wragg85, N. Mannion34, S. Chu63, M. Ukash75, V. Steventon-Jones46, J. Fairley84, H. Northen18, D. Babu75, L. Donaghy34, J. Jimmy48, B. Matharu18, J. Beasley42, S. Waller75, C. Batterton63, G. Baker4, J. Trotman4, L. Jackson11, A. Visavadia63, M. Domeradzka49, M. Slater22, K. Annesley18, C. Andrews1, J. Doughty18, E. Wall63, S. Morosini46, E. Hanney60
dc.description.abstractPurpose Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare cancer susceptibility syndrome exclusively attributable to pathogenic variants in FH. This paper quantitatively weights the phenotypic context (PP4/PS4) of such very rare variants in FH. Methods We collated clinical diagnostic testing data on germline FH variants from 387 individuals with HLRCC and 1,780 individuals with renal cancer, and compared the frequency of ‘very rare’ variants in each phenotypic cohort against 562,295 population controls. We generated pan-gene very rare variant likelihood ratios (PG-VRV-LRs), domain-specific likelihood ratios for missense variants (DS-VRMV-LR) using spatial clustering analysis, and log₂.₀₈ likelihood ratios (LLRs) as applicable within the updated ACMG/AMP Variant Classification Framework.Results For HLRCC, the PG-VRV-LR was estimated to be 2,669.4 (95% CI: 1,843.4-3,881.2, LLR 10.77) for truncating variants and 214.7 (185.0-246.9, LLR 7.33) for missense variants. For renal cancer, the PG-VRV-LR was 95.5 (48.9-183.0, LLR 6.23) for truncating variants and 5.8 (3.5-9.3, LLR 2.39) for missense variants. Clustering analysis in HLRCC cases revealed three ‘hotspot’ regions wherein the DS-VRMV-LR increased to 1226.9. Conclusion These data provide quantitative measures for very rare missense and truncating variants in FH, which reflect the differing phenotypic specificity of HLRCC and renal cancer, and may be applicable in clinical variant classification.
dc.description.urihttps://www.medrxiv.org/content/10.1101/2025.03.17.25324088v1
dc.format.extent26 pages
dc.genrejournal articles
dc.genrepreprints
dc.identifierdoi:10.13016/m2yfao-xk61
dc.identifier.urihttps://doi.org/10.1101/2025.03.17.25324088
dc.identifier.urihttp://hdl.handle.net/11603/41656
dc.language.isoen
dc.relation.isAvailableAtThe University of Maryland, Baltimore County (UMBC)
dc.relation.ispartofUMBC Faculty Collection
dc.relation.ispartofUMBC Biological Sciences Department
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleQuantifying evidence for phenotypic specificity (PP4) for syndromic phenotypes: Large-scale integration of rare germline FH variants from diagnostic laboratory testing for HLRCC (Hereditary Leiomyomatosis and Renal Cell Cancer) and renal cancer
dc.typeText
dcterms.creatorhttps://orcid.org/0000-0003-4666-6118

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
2025031725324088v1full.pdf
Size:
311.08 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
supplement16.zip
Size:
295.94 KB
Format:
Unknown data format